Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT04512287
PHASE2

PRP for Treatment of Peyronie's Disease

Sponsor: University of Miami

View on ClinicalTrials.gov

Summary

The purpose of this study is to learn about the effects of Platelet-Rich Plasma (PRP) injection in men with Peyronie's Disease (PyD).

Official title: A Randomized, Double-Blind, Placebo Controlled, Crossover Trial on Safety and Efficacy of Autologous Platelet-Rich Plasma for Treatment of Peyronie's Disease

Key Details

Gender

MALE

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

65

Start Date

2021-03-29

Completion Date

2025-08-11

Last Updated

2026-08-03

Healthy Volunteers

No

Interventions

BIOLOGICAL

Autologous Platelet-Rich Plasma (PRP)

Autologous platelet-rich plasma (PRP) prepared from the participant's own blood. Participants will receive 2 treatment sessions administered 15 ± 7 days apart, with 0.5 mL of PRP injected into the Peyronie's disease penile plaque at each session.

OTHER

Placebo (Normal Saline)

Normal saline administered as a placebo comparator. Participants will receive 2 treatment sessions administered 15 ± 7 days apart, with 0.5 mL of normal saline injected into the Peyronie's disease penile plaque at each session.

Locations (1)

University of Miami

Miami, Florida, United States